Efficacy, Safety, and Tolerability of Sertraline in Patients with Late‐Life Depression and Comorbid Medical Illness

摘要: Objectives: To report on the efficacy, safety, and tolerability of sertraline in treatment elderly depres-sed patients with without comorbid medical illness. Setting: Multicenter. Design: Randomized, double-blind, placebo-controlled study. Participants: A total 752 aged 60 older diagnosis major depressive disorder according to Diagnostic Statistical Manual Mental Disorders, Fourth Edition, diagnosis. Measurements: Outcome measures included 17-item Hamilton Depression Scale (HAMD); Clinical Global Depression—Severity/Improvement (CGI-S/CGI-I); efficacy safety/adverse event assessments; Quality Life, Enjoyment, Satisfaction Questionnaire; Medical Outcomes Study 36-Item Short-Form Health Status Survey. Results: In overall sample, was superior placebo all three primary outcome measures, HAMD, clinical severity change (CGI-S/CGI-I). Furthermore, therapeutic response comparable those or comorbidity, there were no treatment-by–comorbidity group interactions. Sertraline also associated a faster time than (P<.006). Sertraline-treated had similar adverse events discontinuations when compared noncomorbid group. Conclusion: efficacious reducing symptomatology, regardless presence illness. safe well tolerated by